Tapestry Pharmaceuticals to Sell Genomics Assets; Job Cuts to Total 25 Percent

Nov 19, 2004

NEW YORK, Nov. 18 (GenomeWeb News) - Tapestry Pharmaceuticals, formerlly known as NaPro BioTherapeutics, will close most of its genomics division by the end of next year, laying off around 20 people as it closes the division's facility and sells off or licenses out most of its assets, the firm said yesterday in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Privacy Policy Information, Please

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

Moving the Parts About

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Just Skip that Step

The Economist writes that an increasing number of scientific journals don't do peer review.

This Week in Science

In Science this week: genetic overlap among many psychiatric disorders, and more.

Main menu